GLP-1 Eligibility 2026: Who Qualifies for Ozempic, Wegovy, Zepbound & Mounjaro
The single most-asked GLP-1 question in 2026 is some version of “do I qualify?” The answer depends on three things: your BMI, your medical conditions, and your insurance. The BMI math is the same across every drug. The medical-condition rules vary by indication. The insurance gating is where most patients actually get stuck.
We tested the eligibility criteria of every major GLP-1 program in 2026 — manufacturer savings cards, telehealth providers, compounded pharmacies — through realistic patient profiles. This guide maps exactly what gets you through the door for each drug, and what to do when you don't qualify on a clean read.
The BMI rules: same math, drug-specific application
BMI (body mass index) is calculated as weight in kilograms divided by height in meters squared. The two thresholds that drive GLP-1 eligibility are 27 and 30. Everyone uses these — manufacturers, insurance companies, telehealth providers, and compounding pharmacies. The differences come from how each adds the comorbidity layer.
BMI ≥30 alone qualifies you for Wegovy, Zepbound, or Saxenda — no comorbidity required. This is the cleanest path. About 42% of U.S. adults meet this criterion, per CDC data.
BMI 27–29.9 plus one comorbidity also qualifies. The comorbidities that count: Type 2 diabetes, hypertension (≥130/85), dyslipidemia (high cholesterol), obstructive sleep apnea, established cardiovascular disease, or polycystic ovary syndrome (PCOS — increasingly accepted by insurers as a qualifying comorbidity).
BMI <27doesn't qualify for branded weight-management GLP-1s through standard pathways. Some compounded programs have more flexible criteria, and some clinicians will prescribe off-label for patients with BMI 25–27 who have metabolic-syndrome features, but insurance coverage in this range is rare.
The diabetes path: Ozempic, Mounjaro, Rybelsus
Ozempic, Mounjaro, and Rybelsus are FDA-approved for Type 2 diabetes. The eligibility question is binary: do you have a documented Type 2 diabetes diagnosis (ICD-10 E11.x)? If yes, you qualify regardless of BMI. If no, the on-label path closes — but the BMI path through Wegovy or Zepbound usually opens instead.
Type 2 diabetes is typically diagnosed by an A1C of 6.5% or higher (on two occasions), fasting plasma glucose ≥126 mg/dL, or a 2-hour OGTT ≥200 mg/dL. Prediabetes (A1C 5.7–6.4%) does NOT count as Type 2 for GLP-1 eligibility.
Off-label diabetes-drug use for weight loss is widespread but insurance-fraught. Many clinicians prescribe Ozempic for weight loss in patients without diabetes; the prescription is legal, but insurance coverage almost never follows. Patients pursuing this route should expect cash-pay or use compounded semaglutide as the cost-controlled alternative.
The BMI math is identical across drugs. What changes is which insurance pathway your specific situation unlocks — and that's where most patients actually get stuck.
The insurance reality: prior authorization is the real gate
Meeting the FDA criteria is necessary but not sufficient for insurance coverage. Most commercial plans require a prior authorization (PA) for Wegovy, Zepbound, and other weight-management GLP-1s. The PA typically asks for documented attempts at diet, exercise, and behavioral interventions over 3–6 months before drug therapy.
What gets PAs approved fast:a clinician's note documenting prior diet/exercise attempts (commercial weight-loss program, dietitian visits, Y participation, documented kcal deficit attempts), specific BMI measurement at point of prescription, and clearly named comorbidity if BMI is in the 27–29.9 range. Telehealth providers with dedicated PA teams (Ro, Found, WeightWatchers Clinic, LifeMD) routinely close approvals in 3–10 business days versus 4–6 weeks at most primary-care offices.
What gets PAs denied: off-label prescribing for non-diabetic patients on Ozempic or Mounjaro, missing comorbidity documentation in the 27–29.9 BMI range, or insufficient documentation of prior diet/exercise attempts.
If your PA gets denied: appeal once with strengthened documentation. If the appeal also fails, your alternatives are the manufacturer cash-pay program (NovoCare $499/mo, LillyDirect $399 vials) or a compounded program ($179–$499/mo). Federal-plan patients (Medicare, Medicaid, VA) cannot use manufacturer savings cards by law, so for them, compounded becomes a meaningfully important fallback.
When you don't qualify on a strict read
About 30% of patients who want GLP-1 access don't cleanly meet the standard insurance criteria. The honest paths in 2026:
Compounded GLP-1 programs apply clinical judgment but typically use the same BMI criteria as branded products. Some are willing to prescribe to patients with BMI 25–27 who have metabolic-syndrome features. Cash-pay only — no insurance layer, no PA fight, no formal coverage criteria beyond clinician-led judgment.
Off-label prescribing by a primary-care clinician or specialist — legal, common, but cost-prohibitive without insurance. Expect $499–$1,349 per month retail.
Patient assistance programs— Novo Nordisk and Eli Lilly both offer income-based assistance for uninsured patients who meet specific eligibility criteria. These are not the savings card; they're separate need-based programs with stricter documentation but deeper discounts.
GLP-1 eligibility FAQ
What BMI do I need for Wegovy or Zepbound?
BMI ≥30, OR BMI ≥27 with at least one weight-related comorbidity (Type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). This is the FDA-approved indication and what insurance prior authorizations require.
Do I need diabetes for Ozempic or Mounjaro?
Yes — Ozempic and Mounjaro are FDA-approved for Type 2 diabetes, and that's the indication insurance covers. Some clinicians prescribe off-label for weight loss, but insurance coverage for that use is inconsistent and frequently denied.
Can I qualify if I have prediabetes?
Prediabetes alone doesn't qualify you for Ozempic or Mounjaro (those require Type 2 diagnosis). Prediabetes can satisfy the comorbidity requirement for Wegovy or Zepbound if your BMI is ≥27, depending on insurer interpretation.
What if my BMI is 26?
Below the 27 threshold means you don't meet eligibility for branded weight-management drugs (Wegovy, Zepbound, Saxenda). Compounded programs sometimes have more flexible criteria, but reputable ones still apply clinical judgment about whether GLP-1 therapy is appropriate.
Do I need to fail diet and exercise first?
FDA labels and insurance prior authorizations typically expect documented attempts at diet, exercise, and behavioral interventions before GLP-1 therapy. The documentation requirement varies by insurer — some accept a clinician's note, others require formal program enrollment.
Can teens or children qualify?
Wegovy is FDA-approved for adolescents 12+ with BMI in the 95th percentile or above. Zepbound, Ozempic, and Mounjaro are not currently approved for pediatric use. Saxenda is approved for ages 12+ with similar BMI criteria.
What disqualifies me?
Personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2 (MEN 2), severe pancreatitis history, pregnancy or planned pregnancy within 2 months, and active eating disorders. Type 1 diabetes patients aren't candidates for these GLP-1s.
Will my employer's insurance cover GLP-1s?
Coverage varies dramatically by employer. Most large employers cover Type 2 diabetes GLP-1s. Coverage of weight-management GLP-1s (Wegovy, Zepbound) is mixed — about 50–60% of large employer plans cover them in 2026, often with prior authorization, and about 25–30% explicitly exclude weight-loss drugs.
Can Medicare cover Wegovy or Zepbound?
Medicare doesn't traditionally cover weight-loss medications, but coverage expanded modestly in 2024–2025 when Wegovy gained the cardiovascular indication via SELECT. Patients with established CV disease may now qualify for Medicare Part D coverage of Wegovy specifically.
What if I qualify on paper but my doctor won't prescribe?
Telehealth providers (Ro, Found, WeightWatchers Clinic, LifeMD) prescribe GLP-1s if you meet the FDA criteria, even when local clinicians won't. Your eligibility doesn't change — only the prescribing channel.